Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Edwards Lifesciences Corporation stock
Learn how to easily invest in Edwards Lifesciences Corporation stock.
Edwards Lifesciences Corporation is a medical devices business based in the US. Edwards Lifesciences Corporation shares (EW) are listed on the NYSE and all prices are listed in US Dollars. Edwards Lifesciences Corporation employs 14,900 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Edwards Lifesciences Corporation
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – EW – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- EW shares summary
- Compare share dealing platforms
- Is EW stock a buy or sell?
- Stock performance over time
- Is EW suitable for ethical investing?
- Are EW shares over-valued?
- Edwards Lifesciences Corporation's financials
- How volatile are EW shares?
- Does Edwards Lifesciences Corporation pay a dividend?
- Have EW shares ever split?
- Other common questions
Edwards Lifesciences Corporation stock price (NYSE: EW)Use our graph to track the performance of EW stocks over time.
Edwards Lifesciences Corporation shares at a glance
|Latest market close||$115.56|
|52-week range||$78.44 - $131.73|
|50-day moving average||$119.54|
|200-day moving average||$109.27|
|Wall St. target price||$129.52|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.33|
Buy Edwards Lifesciences Corporation shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Edwards Lifesciences Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Edwards Lifesciences Corporation price performance over time
|1 week (2022-01-12)||-5.48%|
|1 month (2021-12-21)||-7.11%|
|3 months (2021-10-17)||N/A|
|6 months (2021-07-21)||8.97%|
|1 year (2021-01-21)||32.48%|
|2 years (2020-01-21)||-52.27%|
|3 years (2019-01-18)||168.41|
|5 years (2017-01-20)||20.99%|
Is Edwards Lifesciences Corporation stock undervalued or overvalued?
Valuing Edwards Lifesciences Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Edwards Lifesciences Corporation's P/E ratio
Edwards Lifesciences Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Edwards Lifesciences Corporation shares trade at around 51x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Edwards Lifesciences Corporation's PEG ratio
Edwards Lifesciences Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.5631. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Edwards Lifesciences Corporation's EBITDA
Edwards Lifesciences Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.7 billion.
The EBITDA is a measure of a Edwards Lifesciences Corporation's overall financial performance and is widely used to measure a its profitability.
Edwards Lifesciences Corporation financials
|Revenue TTM||$5.1 billion|
|Operating margin TTM||31.1%|
|Gross profit TTM||$3.3 billion|
|Return on assets TTM||13.24%|
|Return on equity TTM||30.3%|
|Market capitalisation||$73.8 billion|
TTM: trailing 12 months
Edwards Lifesciences Corporation's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Edwards Lifesciences Corporation's total ESG risk score
Total ESG risk: 21.68
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences Corporation's overall score of 21.68 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Edwards Lifesciences Corporation's environmental score
Environmental score: 4.78/100
Edwards Lifesciences Corporation's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Edwards Lifesciences Corporation's social score
Social score: 13.43/100
Edwards Lifesciences Corporation's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Edwards Lifesciences Corporation's governance score
Governance score: 10.96/100
Edwards Lifesciences Corporation's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Edwards Lifesciences Corporation's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Edwards Lifesciences Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences Corporation has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||21.68|
|Total ESG percentile||24.1|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
|Level of controversy||2|
Edwards Lifesciences Corporation share dividends
We're not expecting Edwards Lifesciences Corporation to pay a dividend over the next 12 months.
Have Edwards Lifesciences Corporation's shares ever split?
Edwards Lifesciences Corporation's shares were split on a 3:1 basis on 31 May 2020. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences Corporation shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences Corporation shares which in turn could have impacted Edwards Lifesciences Corporation's share price.
Edwards Lifesciences Corporation share price volatility
Over the last 12 months, Edwards Lifesciences Corporation's shares have ranged in value from as little as $78.44 up to $131.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences Corporation's is 1.0933. This would suggest that Edwards Lifesciences Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Edwards Lifesciences Corporation overview
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. .
Edwards Lifesciences Corporation in the news
Netflix quietly admits streaming competition is eating into growth
Edwards Lifesciences (EW) to Post Q4 Earnings: What's in Store?
Edwards Lifesciences (EW) to Report Q4 Results: Wall Street Expects Earnings Growth
Frequently asked questionsWhat percentage of Edwards Lifesciences Corporation is owned by insiders or institutions?
Currently 0.739% of Edwards Lifesciences Corporation shares are held by insiders and 85.678% by institutions. How many people work for Edwards Lifesciences Corporation?
Latest data suggests 14,900 work at Edwards Lifesciences Corporation. When does the fiscal year end for Edwards Lifesciences Corporation?
Edwards Lifesciences Corporation's fiscal year ends in December. Where is Edwards Lifesciences Corporation based?
Edwards Lifesciences Corporation's address is: One Edwards Way, Irvine, CA, United States, 92614 What is Edwards Lifesciences Corporation's ISIN number?
Edwards Lifesciences Corporation's international securities identification number is: US28176E1082 What is Edwards Lifesciences Corporation's CUSIP number?
Edwards Lifesciences Corporation's Committee on Uniform Securities Identification Procedures number is: 28176E108
More guides on Finder
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Ask an Expert